drugset / Trial / NCT07331220
Pulmonary Artery Denervation for Heart Failure With Preserved Left Ventricular Ejection Fraction
Not yet recruiting
310 enrolled
Nanjing First Hospital, Nanjing Medical University
Nanjing Medical University · collab
RandomizedParallel-groupTriple-blindTreatment
Summary
To assess the impact of PADN combined with guideline-directed medical therapy (GDMT) versus a sham procedure with GDMT on clinical outcomes in heart failure (HF) patients with preserved left ventricular ejection fraction (LVEF\>40%). Outcomes include cardiovascular death, HF-related rehospitalization, requirement for heart transplantation or need of valvular treatment or LVAD or pacemaker implantation, and worsening in outpatients (defined as requirement for intravenous therapy or diuretic intensification, including increasing the types or dose of diuretics).
Timeline
- Start
- 2026-12-30
- Primary completion
- 2028-12-30
- Completion
- 2028-12-30
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Background | Dapagliflozin | Small molecule | 10 mg | — |
| Background | Empagliflozin | Small molecule | 10 mg | — |
| Background | Spironolactone | Small molecule | 10 mg | — |
| Background | Spironolactone | Small molecule | 20 mg | — |
| Background | Spironolactone | Small molecule | 40 mg | — |